Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul-Dec;19(7):689-692.
doi: 10.1080/1744666X.2023.2207823. Epub 2023 May 11.

Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis

Ilaria Maccora  1   2   3 , Preston Land  3   4 , Virginia Miraldi Utz  4   5 , Sheila T Angeles-Han  3   4   5
Affiliations
Editorial

Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis

Ilaria Maccora et al. Expert Rev Clin Immunol. 2023 Jul-Dec.
No abstract available

Keywords: Baricitinib; JAK-inhibitor; JIA; Uveitis; pediatric uveitis; tofacitinib; treatment; upadacitinib.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1:
Figure 1:
Proposed therapeutic approach based on the 2019 American College of Rheumatology recommendations for the treatment of JIA associated uveitis. List of abbreviations: APC antigen presenting cell, CAU chronic anterior uveitis, d daily, dp drops, EB endothelial barrier, os oral, JAKi Janus Kinase inhibitor, JIA Juvenile Idiopathic Arthritis, MTX Methotrexate, PA prednisone acetate, sc subcutaneous, TNFi Tumor Necrosis factor alpha inhibitor.
See this image and copyright information in PMC

References

    1. Angeles-Han ST, Ringold S, Beukelman T et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis care & research. 71(6), 703–716 (2019) - PMC - PubMed

    2. Updated recommendations for the treatment of JIA-associated uveitis by the American College of Rheumatology for North American

    1. Foeldvari I, Maccora I, Petrushkin H et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis associated uveitis and idiopathic chronic anterior uveitis. Arthritis care & research (2022) - PubMed

    2. Updated recommendations for the treatment of JIA-associated uveitis by the American College of Rheumatology by the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) for Europe

    1. Angeles-Han ST, Srivastava SK. Screening, Monitoring, and Treating Children With Juvenile Idiopathic Arthritis-Associated Uveitis: Visualizing Better Outcomes. The Journal of rheumatology (2022) - PubMed
    1. Maccora I, Fusco E, Marrani E,et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology (Oxford, England). 60(2), 568–587 (2021) - PubMed
    1. Ramanan AV, Dick AD, Jones AP et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. The New England journal of medicine. 376(17), 1637–1646 (2017). - PubMed

Publication types

MeSH terms

Substances